|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO EXP |
[FABP1 protein affects the transport of Dronabinol] which affects the abundance of 11-hydroxy-delta(9)-tetrahydrocannabinol 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] 11-hydroxy-delta(9)-tetrahydrocannabinol affects the folding of and results in increased stability of FABP1 protein; 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein] |
CTD |
PMID:30232874 PMID:31110286 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions |
EXP |
11-hydroxy-delta(9)-tetrahydrocannabinol binds to and results in increased activity of TRPV2 protein |
CTD |
PMID:18550765 |
|
NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
affects metabolic processing |
ISO |
UGT1A9 gene SNP affects the metabolism of 11-hydroxy-delta(9)-tetrahydrocannabinol |
CTD |
PMID:30191314 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of CASP3 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 PMID:31024316 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions |
ISO |
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egf |
epidermal growth factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of EGF mRNA; glyceryl 2-arachidonate affects the expression of EGF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of FGF1 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of GDNF mRNA; glyceryl 2-arachidonate affects the expression of GDNF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases chemical synthesis multiple interactions |
ISO |
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:31408376 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate |
CTD |
PMID:27071101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:26791602 PMID:30301768 More...
|
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 PMID:34756920 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions increases metabolic processing |
ISO |
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] |
CTD |
PMID:29689453 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation increases response to substance decreases metabolic processing multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide] |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:27307500 PMID:27385208 PMID:29787777 PMID:31121907 PMID:37245739 More...
|
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 More...
|
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA |
CTD |
PMID:26468265 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein] |
CTD |
PMID:26467187 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein |
CTD |
PMID:30607903 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cartpt |
CART prepropeptide |
decreases expression multiple interactions |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Cd86 |
CD86 molecule |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:12734338 PMID:27455076 PMID:29033935 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions increases expression |
ISO |
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein |
CTD |
PMID:31912162 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] |
CTD |
PMID:31912162 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA |
CTD |
PMID:22791651 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases expression multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] |
CTD |
PMID:27455076 PMID:30019168 PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions increases expression |
ISO |
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression increases secretion multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein |
CTD |
PMID:27455076 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein] |
CTD |
PMID:26671069 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases expression |
EXP |
arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26671069 PMID:26847930 PMID:30761839 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein] |
CTD |
PMID:32033504 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein] |
CTD |
PMID:29033935 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
increases expression |
EXP |
arachidonyl-2-chloroethylamide results in increased expression of OLIG2 protein |
CTD |
PMID:17880390 |
|
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:31256211 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
multiple interactions increases expression |
EXP |
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions decreases expression |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA] arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions increases activity |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:29033935 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein] |
CTD |
PMID:31256211 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:26467187 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ABCB11 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Cannabidiol results in increased expression of ABCB1A mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ABCB4 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ABCB6 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of ABCC1 protein |
CTD |
PMID:18619955 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ABCC2 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ABCC3 mRNA |
CTD |
PMID:31052254 PMID:31518892 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases expression |
ISO |
Cannabidiol results in increased expression of ABHD12 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
Cannabidiol results in increased expression of ABHD3 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428
|
|
G |
Abl2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of ABL2 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in increased expression of ACACA mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of ACACA protein] |
CTD |
PMID:28935932 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:28935932 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ACADVL protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression |
ISO |
Cannabidiol results in increased expression of ACE1 mRNA |
CTD |
PMID:28025562 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of ACIN1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Actn1 |
actinin, alpha 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ACTN1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actr3 |
actin related protein 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ACTR3 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Actr5 |
actin related protein 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ACTR5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:147,282,461...147,295,870
Ensembl chr 3:147,282,624...147,296,110
|
|
G |
Actrt3 |
actin-related protein T3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ACTRT3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 2:112,799,038...112,801,065
Ensembl chr 2:112,799,011...112,801,075
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
increases expression |
ISO |
Cannabidiol results in increased expression of ADAM9 mRNA |
CTD |
PMID:28025562 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of ADCY5 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ADCY9 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression |
ISO |
Cannabidiol results in increased expression of ADH7 mRNA |
CTD |
PMID:31518892 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:30382123 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in decreased expression of ADIPOR1 mRNA] |
CTD |
PMID:28935932 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Adm |
adrenomedullin |
increases expression |
ISO |
Cannabidiol results in increased expression of ADM mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases expression |
EXP |
Cannabidiol results in decreased expression of ADRB1 protein |
CTD |
PMID:33338514 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Aftph |
aftiphilin |
increases expression |
ISO |
Cannabidiol results in increased expression of AFTPH mRNA |
CTD |
PMID:27918106 |
|
NCBI chr14:94,871,429...94,925,625
Ensembl chr14:94,871,429...94,925,376
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
ISO |
Cannabidiol results in increased expression of AGTRAP mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR protein affects the reaction [Cannabidiol results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:26187180 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aicda |
activation-induced cytidine deaminase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AICDA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of AICDA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Ketamine results in decreased expression of AIF1 mRNA] |
CTD |
PMID:31823199 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of AIFM1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in decreased expression of AIMP1 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728
|
|
G |
Ak1 |
adenylate kinase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of AK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
ISO |
Cannabidiol results in increased expression of AKR1B7 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation increases phosphorylation increases expression decreases expression affects expression multiple interactions |
ISO |
Cannabidiol results in decreased phosphorylation of AKT1 protein Cannabidiol results in increased phosphorylation of AKT1 protein Cannabidiol results in increased expression of AKT1 mRNA Cannabidiol results in decreased expression of AKT1 mRNA Cannabidiol affects the expression of AKT1 protein [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of AKT1 mRNA; Acetylcysteine inhibits the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of AKT1 protein]; Cannabidiol results in decreased phosphorylation of and results in decreased expression of AKT1 protein modified form; LAIR1 protein affects the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of AKT1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of AKT1 protein] |
CTD |
PMID:26504004 PMID:27932991 PMID:28025562 PMID:28392768 PMID:30713602 PMID:31801206 PMID:32992648 PMID:33019509 PMID:33817834 PMID:34575494 PMID:36810933 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of AKT1S1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of AKT2 mRNA |
CTD |
PMID:32992648 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ALCAM mRNA |
CTD |
PMID:27932991 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ALDH9A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ALDOC protein |
CTD |
PMID:34122009 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alg6 |
ALG6, alpha-1,3-glucosyltransferase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ALG6 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439
|
|
G |
Aloxe3 |
arachidonate epidermal lipoxygenase 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ALOXE3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr10:53,830,219...53,854,328
Ensembl chr10:53,831,264...53,854,328
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Cannabidiol results in increased expression of ALPL mRNA |
CTD |
PMID:33872753 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angpt1 |
angiopoietin 1 |
increases secretion |
ISO |
Cannabidiol results in increased secretion of ANGPT1 protein |
CTD |
PMID:32656944 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angptl3 |
angiopoietin-like 3 |
multiple interactions |
ISO |
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of ANGPTL3 protein] |
CTD |
PMID:30825431 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Angptl6 |
angiopoietin-like 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925
|
|
G |
Anp32b |
acidic nuclear phosphoprotein 32 family member B |
increases expression |
ISO |
Cannabidiol results in increased expression of ANP32B mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 5:60,743,077...60,765,726
Ensembl chr 5:60,743,443...60,765,717
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
Cannabidiol results in increased expression of ANPEP mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Ap1m1 |
adaptor related protein complex 1 subunit mu 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of AP1M1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of AP3B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:25,600,069...25,800,937
Ensembl chr 2:25,600,040...25,800,935
|
|
G |
Ap4e1 |
adaptor related protein complex 4 subunit epsilon 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of AP4E1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:114,272,997...114,339,484
Ensembl chr 3:114,272,956...114,336,752
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions decreases expression increases expression |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of APAF1 mRNA Cannabidiol results in decreased expression of APAF1 mRNA Cannabidiol results in increased expression of APAF1 protein |
CTD |
PMID:27932991 PMID:30096889 PMID:31349651 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of APBB3 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr18:28,273,168...28,280,347
Ensembl chr18:28,270,545...28,280,094
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of APC2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:9,392,336...9,414,364
Ensembl chr 7:9,392,336...9,414,310
|
|
G |
Aph1a |
aph-1 homolog A, gamma secretase subunit |
decreases expression |
ISO |
Cannabidiol results in decreased expression of APH1A mRNA |
CTD |
PMID:28025562 |
|
NCBI chr 2:183,437,676...183,443,113
Ensembl chr 2:183,438,434...183,441,955
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] [Cannabidiol co-treated with moringin] results in decreased expression of APP mRNA; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [APP gene mutant form co-treated with PSEN1 gene mutant form] |
CTD |
PMID:21350020 PMID:27567873 PMID:30096889 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of AQP1 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions increases expression |
ISO |
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] Cannabidiol results in increased expression of AQP3 mRNA; Cannabidiol results in increased expression of AQP3 protein |
CTD |
PMID:31054246 PMID:34577578 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
Cannabidiol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AQP9 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of AQP9 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Cannabidiol results in increased expression of AREG mRNA |
CTD |
PMID:33244087 PMID:36519830 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of ARG1 protein] |
CTD |
PMID:30825431 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ARG2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arglu1 |
arginine and glutamate rich 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of ARGLU1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349
|
|
G |
Arl1 |
ADP-ribosylation factor like GTPase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of ARL1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARPC1A gene |
CTD |
PMID:30521419 |
|
NCBI chr12:9,502,496...9,525,304
Ensembl chr12:9,502,501...9,525,330
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARRB2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ARRDC3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ASAH1 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ASB2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of ASNS mRNA Cannabidiol results in increased expression of ASNS mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Cannabidiol results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atad5 |
ATPase family, AAA domain containing 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ATAD5 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr10:65,070,682...65,118,489
Ensembl chr10:65,070,689...65,117,845
|
|
G |
Atat1 |
alpha tubulin acetyltransferase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ATAT1 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr20:2,844,595...2,857,809
Ensembl chr20:2,844,616...2,861,964
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of ATF3 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of ATF3 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA] |
CTD |
PMID:21542829 PMID:26504004 PMID:27256343 PMID:33244087 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF4 mRNA |
CTD |
PMID:21542829 PMID:30307084 PMID:33019509 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF5 mRNA |
CTD |
PMID:21542829 PMID:30307084 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG12 mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg4a |
autophagy related 4A, cysteine peptidase |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of ATG4A mRNA |
CTD |
PMID:33096116 |
|
NCBI chr X:104,665,345...104,765,271
Ensembl chr X:104,665,345...104,765,268
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG4B mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr 9:94,282,417...94,314,109
Ensembl chr 9:94,282,509...94,314,103
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATG7 protein |
CTD |
PMID:38583854 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of ATM mRNA Cannabidiol results in increased expression of ATM protein |
CTD |
PMID:30096889 PMID:31349651 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of ATP1A1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATP2A3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ATP5F1A protein |
CTD |
PMID:34122009 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in increased expression of ATP5PO protein |
CTD |
PMID:34122009 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of ATP6V1A protein |
CTD |
PMID:34122009 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
ISO |
Cannabidiol results in increased expression of AURKB mRNA |
CTD |
PMID:27918106 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Avil |
advillin |
increases expression |
ISO |
Cannabidiol results in increased expression of AVIL mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:62,825,459...62,844,103
Ensembl chr 7:62,826,025...62,844,071
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of AVPR1A mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Axin2 |
axin 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of AXIN2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cannabidiol results in increased expression of AXL mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Azi2 |
5-azacytidine induced 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of AZI2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 8:117,773,248...117,797,844
Ensembl chr 8:117,773,279...117,797,847
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Cannabidiol results in decreased expression of B2M mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BACE1 mRNA |
CTD |
PMID:28025562 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression decreases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of BACH1 mRNA Cannabidiol results in decreased expression of BACH1 protein BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; leptomycin B inhibits the reaction [Cannabidiol results in decreased expression of BACH1 protein] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of BACH1 mRNA |
CTD |
PMID:30742662 PMID:31518892 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression decreases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of BAD protein Cannabidiol results in decreased expression of BAD mRNA [Cannabidiol co-treated with moringin] results in decreased expression of BAD mRNA |
CTD |
PMID:27932991 PMID:30096889 PMID:31349651 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO |
Cannabidiol results in increased expression of BAX mRNA; Cannabidiol results in increased expression of BAX protein Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX protein] [Cannabidiol co-treated with moringin] results in decreased expression of BAX mRNA; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX protein]; iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of BAX protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of BAX protein] |
CTD |
PMID:27932991 PMID:30096889 PMID:31349651 PMID:33244087 PMID:34575494 PMID:36810933 PMID:36988283 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of BAZ1B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:21,431,985...21,489,956
Ensembl chr12:21,431,985...21,490,426
|
|
G |
Bbs5 |
Bardet-Biedl syndrome 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of BBS5 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:54,410,429...54,431,831
Ensembl chr 3:54,410,775...54,431,829
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP ISO |
Cannabidiol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of BCL2 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of BCL2 protein] Cannabidiol results in increased expression of BCL2 protein Cannabidiol results in decreased expression of BCL-2 protein; Cannabidiol results in decreased expression of BCL2 mRNA; Cannabidiol results in decreased expression of BCL2 protein |
CTD |
PMID:27430346 PMID:27932991 PMID:31349651 PMID:33244087 PMID:34575494 PMID:36810933 PMID:36988283 PMID:37625625 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of BCL2A1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression decreases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of BCL2L1 mRNA Cannabidiol results in decreased expression of BCL2L1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of BCL2L1 mRNA; [Cannabidiol results in increased expression of MIR1972-2 mRNA] which results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:30096889 PMID:30713602 PMID:33019509 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bcl7b |
BAF chromatin remodeling complex subunit BCL7B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BCL7B mRNA |
CTD |
PMID:27918106 PMID:27932991 |
|
NCBI chr12:21,496,860...21,510,079
Ensembl chr12:21,496,856...21,510,202
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
increases expression |
ISO |
Cannabidiol results in increased expression of BCL9 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Bcorl1 |
BCL6 co-repressor-like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of BCORL1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP ISO |
Cannabidiol results in increased expression of BDNF protein [Cannabidiol co-treated with moringin] results in increased expression of BDNF protein |
CTD |
PMID:19939866 PMID:30096889 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA] [PSEN1 protein affects the susceptibility to Cannabidiol] which results in increased expression of BECN1 protein Cannabidiol results in increased expression of BECN1 mRNA; Cannabidiol results in increased expression of BECN1 protein |
CTD |
PMID:30074247 PMID:33096116 PMID:33244087 PMID:38583854 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Cannabidiol results in increased expression of BGLAP protein |
CTD |
PMID:32656944 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BID mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of BIRC2 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of BIRC5 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BLM mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Bloc1s2 |
biogenesis of lysosomal organelles complex-1, subunit 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of BLOC1S2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 1:243,024,611...243,031,749
Ensembl chr 1:243,024,614...243,031,653
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Cannabidiol results in increased expression of BLVRB mRNA |
CTD |
PMID:31518892 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of BMAL1 mRNA |
CTD |
PMID:30307084 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of BMP2 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression increases expression |
ISO |
Cannabidiol results in decreased expression of BMP4 mRNA Cannabidiol results in increased expression of BMP4 mRNA |
CTD |
PMID:27918106 PMID:33244087 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP6 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP7 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bnc2 |
basonuclin zinc finger protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of BNC2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426
|
|
G |
Bora |
bora, aurora kinase A activator |
increases expression |
ISO |
Cannabidiol results in increased expression of BORA mRNA |
CTD |
PMID:27918106 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of BRAF mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of BRAF mRNA |
CTD |
PMID:30096889 PMID:32992648 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression multiple interactions increases expression |
ISO |
Cannabidiol results in decreased expression of BRCA1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of BRCA1 mRNA Cannabidiol results in increased expression of BRCA1 mRNA |
CTD |
PMID:27918106 PMID:30096889 PMID:33244087 PMID:36519830 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions decreases expression |
ISO |
[Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in decreased expression of BRCA2 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in increased expression of BRCA2 mRNA] |
CTD |
PMID:32992648 PMID:36519830 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Brcc3 |
BRCA1/BRCA2-containing complex subunit 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BRCC3 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080
|
|
G |
Brip1 |
BRCA1 interacting helicase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BRIP1 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324
|
|
G |
Bsg |
basigin |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of BSG mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA; Cannabidiol promotes the reaction [Dronabinol results in decreased expression of BSG mRNA]; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of BSG mRNA] |
CTD |
PMID:27769052 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Btd |
biotinidase |
increases expression |
ISO |
Cannabidiol results in increased expression of BTD mRNA |
CTD |
PMID:27918106 |
|
NCBI chr16:6,863,068...6,894,345
Ensembl chr16:6,862,407...6,940,945
|
|
G |
Btla |
B and T lymphocyte associated |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA] Cannabidiol results in increased expression of BTLA mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BUB1 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of BUB1B mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C15h14orf119 |
similar to human chromosome 14 open reading frame 119 |
increases expression |
ISO |
Cannabidiol results in increased expression of C14ORF119 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr15:28,146,368...28,151,422
Ensembl chr15:28,146,333...28,155,180
|
|
G |
C18h18orf54 |
similar to human chromosome 18 open reading frame 54 |
increases expression |
ISO |
Cannabidiol results in increased expression of C18ORF54 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr18:64,065,125...64,090,260
Ensembl chr18:64,065,740...64,089,415
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
Cannabidiol results in decreased expression of C1QA mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
ISO |
Cannabidiol results in increased expression of C1QBP mRNA |
CTD |
PMID:27714895 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
C1qc |
complement C1q C chain |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Ketamine results in decreased expression of C1QC mRNA] |
CTD |
PMID:31823199 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C20h21orf58 |
similar to human chromosome 21 open reading frame 58 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of C21ORF58 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr20:12,167,279...12,188,665
Ensembl chr20:12,175,442...12,187,017
|
|
G |
C2h5orf34 |
similar to human chromosome 5 open reading frame 34 |
increases expression |
ISO |
Cannabidiol results in increased expression of C5ORF34 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 2:51,553,223...51,577,090
Ensembl chr 2:51,555,432...51,577,085
|
|
G |
C3h11orf96 |
similar to human chromosome 11 open reading frame 96 |
increases expression |
ISO |
Cannabidiol results in increased expression of C11ORF96 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:79,920,129...79,921,523
|
|
G |
C4h2orf42 |
similar to human chromosome 2 open reading frame 42 |
increases expression |
ISO |
Cannabidiol results in increased expression of C2ORF42 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 4:118,887,688...118,916,808
Ensembl chr 4:118,888,112...118,916,936
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in decreased expression of C5 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C9h6orf141 |
similar to human chromosome 6 open reading frame 141 |
increases expression |
ISO |
Cannabidiol results in increased expression of C6ORF141 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:20,024,916...20,029,094
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CABIN1 mRNA |
CTD |
PMID:27714895 |
|
NCBI chr20:12,893,314...13,015,357
Ensembl chr20:12,893,358...13,015,357
|
|
G |
Cabyr |
calcium binding tyrosine phosphorylation regulated |
increases expression |
ISO |
Cannabidiol results in increased expression of CABYR mRNA |
CTD |
PMID:27918106 |
|
NCBI chr18:3,892,062...3,904,391
Ensembl chr18:3,892,132...3,903,840
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1A gene |
CTD |
PMID:30521419 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1G gene |
CTD |
PMID:30521419 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1I gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
|
|
G |
Cacybp |
calcyclin binding protein |
increases expression |
ISO |
Cannabidiol results in increased expression of CACYBP mRNA |
CTD |
PMID:27918106 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAMK2A mRNA |
CTD |
PMID:28025562 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:28025562 PMID:33019509 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camta1 |
calmodulin binding transcription activator 1 |
decreases methylation |
ISO |
Cannabidiol results in decreased methylation of CAMTA1 gene |
CTD |
PMID:33407853 |
|
NCBI chr 5:161,510,283...162,356,902
Ensembl chr 5:161,510,283...162,356,723
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAPN1 mRNA |
CTD |
PMID:28025562 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CAPN2 mRNA [Cuprizone co-treated with Cannabidiol] results in decreased expression of CAPN2 protein |
CTD |
PMID:28025562 PMID:34122009 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capn3 |
calpain 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAPN3 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAR3 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CARS1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
decreases methylation |
ISO |
Cannabidiol results in decreased methylation of CASK gene |
CTD |
PMID:33407853 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp1 |
caspase 1 |
multiple interactions decreases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP1 protein]]; AM 251 inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]]; Cannabidiol binds to and results in decreased activity of CASP1 protein; Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP1 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP1 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of CASP1 protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of CASP1 protein] Cannabidiol results in decreased expression of CASP1 mRNA; Cannabidiol results in decreased expression of CASP1 protein |
CTD |
PMID:27932991 PMID:33955754 PMID:34269108 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Methotrexate results in increased expression of CASP12 mRNA] |
CTD |
PMID:37927177 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CASP2 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases cleavage |
ISO EXP |
[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 mRNA; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased cleavage of CASP3 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CASP3 mRNA]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein] Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased cleavage of CASP3 protein]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CASP3 mRNA] Cannabidiol results in increased expression of CASP3 mRNA Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:27430346 PMID:30713602 PMID:31349651 PMID:31699976 PMID:32708634 PMID:32733202 PMID:32992648 PMID:33076330 PMID:33244087 PMID:36810933 PMID:36988283 PMID:37625625 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression decreases expression |
ISO |
Cannabidiol results in increased expression of CASP4 mRNA Cannabidiol results in decreased expression of CASP4 mRNA |
CTD |
PMID:21542829 PMID:27932991 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CASP6 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CASP6 mRNA |
CTD |
PMID:27932991 PMID:30096889 PMID:33019509 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
increases cleavage multiple interactions increases expression |
ISO |
Cannabidiol results in increased cleavage of CASP7 protein [Cannabidiol co-treated with moringin] results in decreased expression of CASP7 mRNA Cannabidiol results in increased expression of CASP7 mRNA; Cannabidiol results in increased expression of CASP7 protein |
CTD |
PMID:30096889 PMID:33244087 PMID:34575494 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
decreases expression multiple interactions increases cleavage |
ISO |
Cannabidiol results in decreased expression of CASP8 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CASP8 mRNA Cannabidiol results in increased cleavage of CASP8 protein |
CTD |
PMID:27932991 PMID:30096889 PMID:31699976 PMID:31801206 PMID:33019509 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CASP8AP2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions increases activity increases cleavage |
ISO EXP |
Cannabidiol results in increased expression of CASP9 mRNA Cannabidiol inhibits the reaction [Methotrexate results in increased expression of CASP9 mRNA] Cannabidiol results in increased activity of CASP9 protein Cannabidiol results in increased cleavage of CASP9 protein 3-methyladenine inhibits the reaction [Cannabidiol results in increased activity of CASP9 protein]; [Cannabidiol co-treated with moringin] results in decreased expression of CASP9 mRNA |
CTD |
PMID:30096889 PMID:31349651 PMID:31699976 PMID:33244087 PMID:34302491 PMID:36810933 PMID:37927177 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity increases expression multiple interactions |
ISO |
Cannabidiol results in decreased activity of CAT protein Cannabidiol results in increased expression of CAT protein Cannabidiol inhibits the reaction [Haloperidol results in decreased activity of CAT protein] |
CTD |
PMID:30217539 PMID:32752303 PMID:34774840 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbfb |
core-binding factor subunit beta |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CBFB mRNA |
CTD |
PMID:27918106 |
|
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Cbx8 |
chromobox 8 |
multiple interactions increases expression |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of CBX8 mRNA] Cannabidiol results in increased expression of CBX8 mRNA |
CTD |
PMID:27918106 PMID:30825431 |
|
NCBI chr10:104,294,518...104,296,956
Ensembl chr10:104,294,518...104,297,024
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc110 |
coiled-coil domain containing 110 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CCDC110 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:46,315,745...46,337,050
Ensembl chr16:46,315,745...46,337,021
|
|
G |
Ccdc142 |
coiled-coil domain containing 142 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCDC142 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 4:115,606,151...115,616,223
Ensembl chr 4:115,608,485...115,616,216
|
|
G |
Ccdc7b |
coiled-coil domain containing 7B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCDC7 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr19:57,182,480...57,255,764
Ensembl chr19:57,182,509...57,255,763
|
|
G |
Ccdc8 |
coiled-coil domain containing 8 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCDC8 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:77,679,521...77,682,849
Ensembl chr 1:77,679,218...77,683,090
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL1 mRNA] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CCL1 mRNA |
CTD |
PMID:31250491 PMID:32400224 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCL2 mRNA [Cannabidiol co-treated with Pam(3)CSK(4) peptide] results in increased secretion of CCL2 protein; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Cannabidiol promotes the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of CCL2 protein] Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of CCL2 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] |
CTD |
PMID:19910459 PMID:21542829 PMID:28935932 PMID:30033591 PMID:31250491 PMID:34740670 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CCL20 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL20 mRNA] |
CTD |
PMID:31250491 PMID:33244087 PMID:36519830 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCL22 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA] |
CTD |
PMID:30742662 PMID:31250491 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in decreased expression of CCL26 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCL7 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL7 mRNA] |
CTD |
PMID:21542829 PMID:31250491 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CCN2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn4 |
cellular communication network factor 4 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of WISP1 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 7:98,645,238...98,677,253
Ensembl chr 7:98,645,182...98,677,248
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CCNA2 mRNA Cannabidiol results in decreased expression of CCNA2 mRNA |
CTD |
PMID:32992648 PMID:36519830 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in decreased expression of CCNB1 mRNA] Cannabidiol results in decreased expression of CCNB1 mRNA |
CTD |
PMID:32992648 PMID:36519830 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCNB2 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCND1 mRNA; Cannabidiol results in decreased expression of CCND1 protein [Cannabidiol co-treated with moringin] results in increased expression of CCND1 mRNA; Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in decreased expression of CCND1 mRNA] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21542829 PMID:30007266 PMID:30096889 PMID:30742662 PMID:32992648 PMID:34871667 PMID:36810933 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCND3 mRNA; Cannabidiol results in decreased expression of CCND3 protein |
CTD |
PMID:34871667 PMID:36519830 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccndbp1 |
cyclin D1 binding protein 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCNDBP1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:107,962,402...107,974,234
Ensembl chr 3:107,962,261...107,974,233
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCNE1 mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CCNE1 mRNA Cannabidiol results in decreased expression of CCNE1 mRNA; Cannabidiol results in decreased expression of CCNE1 protein |
CTD |
PMID:21542829 PMID:31349651 PMID:32992648 PMID:33244087 PMID:36519830 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCNE2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCNE2 mRNA |
CTD |
PMID:21542829 PMID:30742662 PMID:36519830 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCNF mRNA |
CTD |
PMID:33244087 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of CCR5 mRNA] |
CTD |
PMID:30825431 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in decreased expression of CCR6 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Cct4 |
chaperonin containing TCP1 subunit 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CCT4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:96,991,853...97,004,732
Ensembl chr14:96,991,859...97,005,267
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CCT6A protein [Cuprizone co-treated with Cannabidiol] results in decreased expression of CCT6A protein |
CTD |
PMID:34122009 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd109 |
CD109 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD109 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 8:79,454,480...79,569,195
Ensembl chr 8:79,454,480...79,569,194
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
[Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CD14 mRNA |
CTD |
PMID:32400224 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD151 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Cannabidiol results in increased expression of CD274 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd276 |
Cd276 molecule |
increases expression |
ISO |
Cannabidiol results in increased expression of CD276 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cd33 |
CD33 molecule |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of CD33 mRNA] |
CTD |
PMID:30825431 |
|
NCBI chr 1:93,935,418...93,940,452
Ensembl chr 1:93,930,971...93,950,149
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of CD34 protein] |
CTD |
PMID:30825431 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD40 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD44 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd46 |
CD46 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD46 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
ISO |
Cannabidiol results in increased expression of CD47 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Cannabidiol results in increased expression of CD55 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd59b |
CD59b molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD59 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD68 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd81 |
Cd81 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD81 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd82 |
Cd82 molecule |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD82 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
|
|
G |
Cd99 |
CD99 molecule (Xg blood group) |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD99 mRNA |
CTD |
PMID:27932991 |
|
NCBI chr20:54,418,239...54,422,882
|
|
G |
Cdc14b |
cell division cycle 14B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC14B mRNA |
CTD |
PMID:31052254 |
|
NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC20 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CDC25A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CDC25A mRNA |
CTD |
PMID:21542829 PMID:30742662 PMID:36519830 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC25B mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC25C mRNA |
CTD |
PMID:36519830 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CDC37 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC42 protein |
CTD |
PMID:37625625 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC45 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC6 mRNA |
CTD |
PMID:21542829 PMID:36519830 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDCA5 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with Dronabinol] results in increased expression of CDH1 protein; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CDH1 mRNA] |
CTD |
PMID:31250491 PMID:37567336 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
affects expression decreases expression multiple interactions |
ISO |
Cannabidiol affects the expression of CDK1 protein Cannabidiol results in decreased expression of CDK1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of CDK1 mRNA; tanespimycin affects the reaction [Cannabidiol affects the expression of CDK1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of CDK1 protein] |
CTD |
PMID:26504004 PMID:30096889 PMID:36519830 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CDK2 mRNA Cannabidiol results in decreased expression of CDK2 protein Cannabidiol results in decreased expression of CDK2 mRNA; Cannabidiol results in decreased expression of CDK2 protein |
CTD |
PMID:31349651 PMID:32992648 PMID:34871667 PMID:36519830 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions decreases expression |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CDK4 mRNA Cannabidiol results in decreased expression of CDK4 protein |
CTD |
PMID:32992648 PMID:34871667 PMID:36810933 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDK5 mRNA |
CTD |
PMID:27918106 PMID:28025562 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions decreases expression |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA] Cannabidiol results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:27256343 PMID:28025562 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk5rap1 |
CDK5 regulatory subunit associated protein 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDK5RAP1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:142,838,081...142,872,669
Ensembl chr 3:142,708,028...142,872,677
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDK6 protein |
CTD |
PMID:34871667 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CDKN1A mRNA Cannabidiol results in decreased expression of CDKN1A mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CDKN1A mRNA Cannabidiol results in increased expression of CDKN1A mRNA; Cannabidiol results in increased expression of CDKN1A protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CDKN1A mRNA |
CTD |
PMID:21542829 PMID:27918106 PMID:30096889 PMID:30742662 PMID:31052254 PMID:31349651 PMID:36519830 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions decreases expression |
ISO EXP |
Cannabidiol results in increased expression of CDKN2A mRNA Cannabidiol results in increased expression of CDKN2A mRNA; Cannabidiol results in increased expression of CDKN2A protein Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in increased expression of CDKN2A mRNA] Cannabidiol results in decreased expression of CDKN2A mRNA |
CTD |
PMID:21542829 PMID:32553926 PMID:32992648 PMID:36519830 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
ISO |
Cannabidiol results in increased expression of CDKN2B mRNA |
CTD |
PMID:21542829 PMID:36519830 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDKN2C mRNA |
CTD |
PMID:33244087 PMID:36519830 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDKN3 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDT1 mRNA |
CTD |
PMID:33244087 PMID:36519830 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cdv3 |
carnitine deficiency-associated gene expressed in ventricle 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of CDV3 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 8:103,934,006...103,947,173
Ensembl chr 8:103,933,996...103,947,192
|
|
G |
Cdyl |
chromodomain Y-like |
increases expression |
ISO |
Cannabidiol results in increased expression of CDYL mRNA |
CTD |
PMID:27918106 |
|
NCBI chr17:28,982,009...29,204,345
Ensembl chr17:28,982,037...29,204,313
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CEBPB mRNA Cannabidiol results in increased expression of CEBPB mRNA |
CTD |
PMID:30742662 PMID:33244087 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cend1 |
cell cycle exit and neuronal differentiation 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CEND1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:196,525,153...196,528,152
Ensembl chr 1:196,523,920...196,528,302
|
|
G |
Cenpe |
centromere protein E |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of CENPE mRNA] |
CTD |
PMID:30825431 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenph |
centromere protein H |
increases expression |
ISO |
Cannabidiol results in increased expression of CENPH mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154
|
|
G |
Cep20 |
centrosomal protein 20 |
increases expression |
ISO |
Cannabidiol results in increased expression of FOPNL mRNA |
CTD |
PMID:27918106 |
|
NCBI chr10:714,051...736,826
Ensembl chr10:714,151...736,837
|
|
G |
Cep290 |
centrosomal protein 290 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CEP290 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392
|
|
G |
Cep78 |
centrosomal protein 78 |
increases expression |
ISO |
Cannabidiol results in increased expression of CEP78 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 1:213,246,183...213,275,275
Ensembl chr 1:213,246,187...213,275,181
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Cannabidiol results in increased expression of CES1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cfap300 |
cilia and flagella associated protein 300 |
increases expression |
ISO |
Cannabidiol results in increased expression of CFAP300 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CFLAR mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CFLAR mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of CFLAR mRNA |
CTD |
PMID:30096889 PMID:30742662 PMID:33096116 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CHAC1 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of CHAC1 mRNA |
CTD |
PMID:21542829 PMID:26504004 PMID:27918106 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CHD2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CHEK1 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions decreases expression |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of CHEK2 mRNA Cannabidiol results in decreased expression of CHEK2 mRNA |
CTD |
PMID:30096889 PMID:36519830 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CHRM2 mRNA; Cannabidiol results in increased expression of CHRM2 protein |
CTD |
PMID:27918106 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CHRNA2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CHRNA7 protein |
CTD |
PMID:24140434 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chst10 |
carbohydrate sulfotransferase 10 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CHST10 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:41,092,805...41,122,737
Ensembl chr 9:41,092,808...41,122,503
|
|
G |
Chst14 |
carbohydrate sulfotransferase 14 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CHST14 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 3:105,916,481...105,918,538
Ensembl chr 3:105,916,466...105,918,548
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases expression |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CHUK mRNA Cannabidiol results in decreased expression of CHUK mRNA |
CTD |
PMID:30096889 PMID:31801206 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cirbp |
cold inducible RNA binding protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CIRBP protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Cannabidiol results in increased expression of CISH mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Cldn1 |
claudin 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CLDN1 protein |
CTD |
PMID:32656944 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn4 |
claudin 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of CLDN4 protein |
CTD |
PMID:32656944 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
increases expression |
ISO |
Cannabidiol results in increased expression of CLEC4E mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Clic1 |
chloride intracellular channel 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CLIC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of CLIP1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884
|
|
G |
Clip3 |
CAP-GLY domain containing linker protein 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CLIP3 mRNA |
CTD |
PMID:31801206 |
|
NCBI chr 1:85,547,170...85,563,187
Ensembl chr 1:85,547,206...85,563,184
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CLOCK mRNA |
CTD |
PMID:30307084 PMID:33019509 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Cmklr2 |
chemerin chemokine-like receptor 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CMKLR2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 9:64,583,310...64,617,883
Ensembl chr 9:64,585,594...64,586,655
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
multiple interactions decreases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CMPK2 protein]]; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein binds to CMPK2 promoter]]; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein results in increased expression of CMPK2 mRNA]]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CMPK2 protein] Cannabidiol results in decreased expression of CMPK2 mRNA; Cannabidiol results in decreased expression of CMPK2 protein |
CTD |
PMID:27256343 PMID:34269108 |
|
NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183
|
|
G |
Cnih2 |
cornichon family AMPA receptor auxiliary protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CNIH2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CNP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression decreases expression affects response to substance |
ISO EXP |
AM 251 inhibits the reaction [Cannabidiol results in increased expression of CNR1 protein]; Cannabidiol analog binds to and results in decreased activity of CNR1 protein; Cannabidiol analog inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; CNR1 polymorphism affects the susceptibility to [Dronabinol co-treated with Cannabidiol]; CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol results in decreased expression of CNR1 protein Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in decreased methylation of CNR1 promoter]; Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of CNR1 mRNA]; Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of CNR1 protein]; Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]] [1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene co-treated with CNR1 protein] affects the susceptibility to Cannabidiol; Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in increased expression of CNR1 mRNA] CNR1 protein affects the susceptibility to Cannabidiol |
CTD |
PMID:20668920 PMID:27932991 PMID:29624642 PMID:30033591 PMID:30496751 PMID:30550613 PMID:31013550 PMID:31202911 PMID:33817834 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects expression |
ISO |
Cannabidiol analog binds to and results in increased activity of CNR2 protein; Cannabidiol analog inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein]; CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in decreased expression of CNR2 mRNA] Cannabidiol affects the expression of CNR2 mRNA |
CTD |
PMID:20668920 PMID:29624642 PMID:30033591 PMID:32733202 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Cannabidiol results in increased expression of COL1A1 mRNA; Cannabidiol results in increased expression of COL1A1 protein |
CTD |
PMID:32656944 PMID:33872753 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:30033591 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of COL3A1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:31250491 PMID:33872753 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of COL4A1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL4A1 mRNA] |
CTD |
PMID:21542829 PMID:31250491 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in increased expression of COL5A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Cannabidiol results in increased expression of COX6A2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CPD mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:61,623,528...61,687,491
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Cpeb1 |
cytoplasmic polyadenylation element binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CPEB1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:135,300,048...135,407,688
Ensembl chr 1:135,300,461...135,409,760
|
|
G |
Cpsf1 |
cleavage and polyadenylation specific factor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CPSF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:108,319,429...108,330,018
Ensembl chr 7:108,319,434...108,329,934
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:28935932 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CRADD mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 7:29,940,240...29,952,907
Ensembl chr 7:29,798,586...29,952,907
|
|
G |
Crb1 |
crumbs cell polarity complex component 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CRB1 gene |
CTD |
PMID:30521419 |
|
NCBI chr13:50,801,484...50,989,261
Ensembl chr13:50,800,959...50,989,261
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation decreases expression multiple interactions |
ISO |
Cannabidiol results in increased phosphorylation of CREB1 protein Cannabidiol results in decreased expression of CREB1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:28601556 PMID:33019509 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3 |
cAMP responsive element binding protein 3 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CREB3 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 5:57,817,865...57,823,233
Ensembl chr 5:57,817,832...57,824,390
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
[Cannabidiol co-treated with Sertraline] results in decreased expression of CRH mRNA |
CTD |
PMID:34262461 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crot |
carnitine O-octanoyltransferase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CROT mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CRTC2 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CRY2 mRNA |
CTD |
PMID:30307084 |
|
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
|
|
G |
Cryl1 |
crystallin, lambda 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CRYL1 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Cryz |
crystallin zeta |
increases expression |
ISO |
Cannabidiol results in increased expression of CRYZ protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CSAD mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF1 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF2 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSF2RA gene |
CTD |
PMID:30521419 |
|
NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CSF3 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF3 mRNA] |
CTD |
PMID:31250491 PMID:33244087 PMID:36519830 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CSK mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSNK1E gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:110,983,322...111,006,926
Ensembl chr 7:110,983,318...111,006,794
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Cstf1 |
cleavage stimulation factor subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CSTF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:161,144,522...161,156,294
Ensembl chr 3:161,144,548...161,156,300
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of CTH mRNA Cannabidiol results in increased expression of CTH mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnd1 |
catenin delta 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in increased expression of CTNND1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctr9 |
CTR9 homolog, Paf1/RNA polymerase II complex component |
increases expression |
ISO |
Cannabidiol results in increased expression of CTR9 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 1:165,137,277...165,167,303
Ensembl chr 1:165,137,215...165,167,303
|
|
G |
Ctsb |
cathepsin B |
decreases expression increases expression |
ISO |
Cannabidiol results in decreased expression of CTSB mRNA Cannabidiol results in increased expression of CTSB mRNA |
CTD |
PMID:27714895 PMID:27932991 PMID:36519830 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of CTSD mRNA |
CTD |
PMID:33096116 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsg |
cathepsin G |
increases expression |
ISO |
Cannabidiol results in increased expression of CTSG mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:29,930,988...29,937,353
Ensembl chr15:29,931,003...29,937,353
|
|
G |
Cul4b |
cullin 4B |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of CUL4B protein |
CTD |
PMID:34122009 |
|
NCBI chr X:117,287,481...117,326,688
Ensembl chr X:117,287,484...117,326,688
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA] Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of CX3CL1 protein] |
CTD |
PMID:30825431 PMID:31250491 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CXCL1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA] |
CTD |
PMID:31250491 PMID:33244087 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA] |
CTD |
PMID:31250491 PMID:32244040 PMID:34740670 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CXCL12 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CXCL14 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CXCL2 mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CXCL2 mRNA; Cannabidiol inhibits the reaction [Ethanol results in increased expression of CXCL2 mRNA] Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL2 mRNA] |
CTD |
PMID:28935932 PMID:31250491 PMID:32400224 PMID:33244087 PMID:36519830 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CXCL1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CXCL1 mRNA |
CTD |
PMID:31250491 PMID:32400224 PMID:33244087 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA] Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL9 mRNA] |
CTD |
PMID:27256343 PMID:31250491 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CXCR4 mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA] Cannabidiol results in increased expression of CXCR4 mRNA |
CTD |
PMID:27769052 PMID:30742662 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYB5R3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in increased expression of CYBB mRNA] |
CTD |
PMID:28935932 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyc1 |
cytochrome c-1 |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of CYC1 mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cannabidiol co-treated with moringin] results in increased expression of CYCS mRNA; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CYCS mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CYCS protein] Cannabidiol inhibits the reaction [Methotrexate results in increased expression of CYCS mRNA] Cannabidiol results in decreased expression of CYCS mRNA Cannabidiol results in increased expression of CYCS protein |
CTD |
PMID:27932991 PMID:30096889 PMID:31349651 PMID:36988283 PMID:37927177 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CYLD mRNA [Cannabidiol co-treated with moringin] results in increased expression of CYLD mRNA |
CTD |
PMID:30096889 PMID:31801206 |
|
NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP19A1 protein Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP1A1 protein Cannabidiol results in increased expression of CYP1A1 mRNA AHR protein affects the reaction [Cannabidiol results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Cannabidiol results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:24667653 PMID:26187180 PMID:31052254 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP1A2 protein Cannabidiol results in increased expression of CYP1A2 mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP1A2 mRNA |
CTD |
PMID:24667653 PMID:31052254 PMID:33096940 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity multiple interactions increases expression |
ISO |
Cannabidiol results in decreased activity of CYP2B6 protein [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2B10 mRNA Cannabidiol results in increased expression of CYP2B10 mRNA Cannabidiol results in decreased activity of CYP2B10 |
CTD |
PMID:8043019 PMID:24667653 PMID:31052254 PMID:33096940 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP2C19 protein [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C29 mRNA |
CTD |
PMID:24667653 PMID:33096940 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions |
ISO |
[Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C66 mRNA |
CTD |
PMID:33096940 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2D6 protein |
CTD |
PMID:21821735 PMID:24667653 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CYP2E1 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions increases metabolic processing |
ISO |
Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] CYP2J2 protein results in increased metabolism of Cannabidiol |
CTD |
PMID:29689453 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP3A4 protein |
CTD |
PMID:24667653 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP3A5 protein |
CTD |
PMID:24667653 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYRIB mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:95,633,876...95,760,588
Ensembl chr 7:95,633,876...95,697,686
|
|
G |
Cyth4 |
cytohesin 4 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Ketamine results in decreased expression of CYTH4 mRNA] |
CTD |
PMID:31823199 |
|
NCBI chr 7:110,152,232...110,176,726
Ensembl chr 7:110,152,272...110,176,741
|
|
G |
Cytip |
cytohesin 1 interacting protein |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYTIP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
|
|
G |
Daglb |
diacylglycerol lipase, beta |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DAGLB mRNA |
CTD |
PMID:27918106 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of DAPK3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:8,524,182...8,532,552
Ensembl chr 7:8,524,183...8,532,558
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DBF4 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dclre1b |
DNA cross-link repair 1B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DCLRE1B mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423
|
|
G |
Dct |
dopachrome tautomerase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DCT mRNA; Cannabidiol results in increased expression of DCT protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of DDIT3 mRNA Cannabidiol inhibits the reaction [Methotrexate results in increased expression of DDIT3 mRNA] Cannabidiol results in increased expression of DDIT3 mRNA; Cannabidiol results in increased expression of DDIT3 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT3 mRNA; DDIT3 protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein]; DDIT3 protein affects the reaction [Cannabidiol results in increased expression of DIABLO protein] [Bilirubin co-treated with Rotenone] promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA] |
CTD |
PMID:21542829 PMID:26504004 PMID:29441458 PMID:31699976 PMID:32033040 PMID:33244087 PMID:37927177 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DDIT4 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of DDIT4 mRNA; [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA |
CTD |
PMID:21542829 PMID:26504004 PMID:30096889 PMID:30742662 PMID:33244087 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DDR1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DDT mRNA |
CTD |
PMID:27932991 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Ddx18 |
DEAD-box helicase 18 |
increases expression |
ISO |
Cannabidiol results in increased expression of DDX18 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr13:32,729,697...32,743,161
Ensembl chr13:32,729,700...32,743,161
|
|
G |
Ddx39a |
DExD-box helicase 39A |
increases expression |
ISO |
Cannabidiol results in increased expression of DDX39 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
increases expression |
ISO |
Cannabidiol results in increased expression of DDX46 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Depdc7 |
DEP domain containing 7 |
increases expression |
ISO |
Cannabidiol results in increased expression of DEPDC7 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of DEPTOR mRNA |
CTD |
PMID:33096116 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DGCR8 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dhx8 |
DEAH-box helicase 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of DHX8 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:86,667,641...86,704,198
Ensembl chr10:86,667,834...86,705,137
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression multiple interactions affects localization decreases expression |
ISO |
Cannabidiol results in increased expression of DIABLO protein [Cannabidiol co-treated with moringin] results in decreased expression of DIABLO mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]]; Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]; DDIT3 protein affects the reaction [Cannabidiol results in increased expression of DIABLO protein]; DIABLO protein affects the reaction [Cannabidiol results in decreased expression of XIAP protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein] Cannabidiol affects the localization of DIABLO protein Cannabidiol results in decreased expression of DIABLO mRNA |
CTD |
PMID:27714895 PMID:30096889 PMID:31699976 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dido1 |
death inducer-obliterator 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DIDO1 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DIO2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dis3 |
DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of DIS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:75,820,040...75,850,450
Ensembl chr15:75,823,436...75,850,642
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of DLD protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
affects methylation multiple interactions |
EXP ISO |
Cannabidiol affects the methylation of DLG4 gene Cannabidiol inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of DLG4 protein] [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein] |
CTD |
PMID:27567873 PMID:30521419 PMID:33817834 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DLGAP1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of DLL1 mRNA] Cannabidiol results in increased expression of DLL1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of DLL4 protein] |
CTD |
PMID:30825431 |
|
NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DLST protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of DLX5 protein |
CTD |
PMID:32656944 |
|
NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
|
|
G |
Dmd |
dystrophin |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG12 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG4B mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ULK1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6RA mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TGFB1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:30074247 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DMP1 mRNA |
CTD |
PMID:33872753 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DNAJB1 mRNA |
CTD |
PMID:26504004 PMID:31518892 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of DNAJB4 mRNA Cannabidiol results in increased expression of DNAJB4 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of DNAJB9 mRNA Cannabidiol results in increased expression of DNAJB9 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression |
ISO |
Cannabidiol results in increased expression of DNER mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in increased expression of DNM2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
decreases methylation |
ISO |
Cannabidiol results in decreased methylation of DNMT3A gene |
CTD |
PMID:32579259 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
increases expression |
ISO |
Cannabidiol results in increased expression of DNMT3L mRNA |
CTD |
PMID:21542829 |
|
NCBI chr20:10,614,933...10,629,337
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Dok2 |
docking protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DOK2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression multiple interactions decreases methylation |
ISO EXP |
Cannabidiol results in decreased expression of DRD2 mRNA Cannabidiol inhibits the reaction [Dronabinol results in decreased methylation of DRD2 gene]; Cannabidiol inhibits the reaction [Dronabinol results in increased expression of DRD2 mRNA] Cannabidiol results in decreased methylation of DRD2 gene |
CTD |
PMID:33019509 PMID:33285233 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of DRD3 mRNA] |
CTD |
PMID:32360362 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dscaml1 |
DS cell adhesion molecule-like 1 |
increases methylation |
ISO |
Cannabidiol results in increased methylation of DSCAML1 gene |
CTD |
PMID:32579259 |
|
NCBI chr 8:45,740,298...46,057,322
Ensembl chr 8:45,740,298...46,057,320
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DSCC1 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dspp |
dentin sialophosphoprotein |
increases expression |
ISO |
Cannabidiol results in increased expression of DSPP mRNA |
CTD |
PMID:33872753 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of DSTN protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DUSP1 mRNA |
CTD |
PMID:21542829 PMID:33244087 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of DUSP4 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of DUSP5 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions increases expression |
ISO |
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA] Cannabidiol results in increased expression of DUSP6 mRNA |
CTD |
PMID:27256343 PMID:33244087 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DYRK1A mRNA |
CTD |
PMID:28025562 |
|
NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression decreases expression |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of E2F1 mRNA Cannabidiol results in increased expression of E2F1 mRNA Cannabidiol results in decreased expression of E2F1 mRNA |
CTD |
PMID:27714895 PMID:27918106 PMID:32992648 PMID:33244087 PMID:36519830 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression decreases expression |
ISO |
Cannabidiol results in increased expression of E2F2 mRNA Cannabidiol results in decreased expression of E2F2 mRNA |
CTD |
PMID:30742662 PMID:33244087 PMID:36519830 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
E2f5 |
E2F transcription factor 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of E2F5 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:86,997,331...87,012,908
Ensembl chr 2:86,997,332...87,012,990
|
|
G |
E2f7 |
E2F transcription factor 7 |
increases expression |
ISO |
Cannabidiol results in increased expression of E2F7 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of ECE1 mRNA |
CTD |
PMID:28025562 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Ect2 |
epithelial cell transforming 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ECT2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [TNF protein results in increased expression of EGF mRNA] |
CTD |
PMID:31250491 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; Cannabidiol inhibits the reaction [TNF protein results in increased expression of EGFR mRNA]; Pertussis Toxin inhibits the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA] |
CTD |
PMID:31250491 PMID:32049991 PMID:32992648 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of EGR1 mRNA Cannabidiol results in decreased expression of EGR1 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of EGR1 mRNA |
CTD |
PMID:26504004 PMID:28344069 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eid2 |
EP300 interacting inhibitor of differentiation 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EID2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:83,538,274...83,539,599
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EIF1 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases expression increases phosphorylation |
ISO |
Cannabidiol results in decreased expression of EIF2AK3 mRNA Cannabidiol results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:31699976 PMID:33019509 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in increased expression of EIF3A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of EIF3B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in decreased expression of EIF4B mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 7:133,206,637...133,228,436
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Cannabidiol co-treated with moringin] results in increased expression of EIF4E mRNA |
CTD |
PMID:30096889 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of EIF4EBP1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:21542829 PMID:30096889 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EIF5A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ELF3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of ELK1 mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ELK1 mRNA |
CTD |
PMID:32992648 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Ell2 |
elongation factor for RNA polymerase II 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ELL2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 2:5,189,375...5,258,781
Ensembl chr 2:5,189,971...5,258,781
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EMC9 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
|
|
G |
Emcn |
endomucin |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of EMCN mRNA] |
CTD |
PMID:30825431 |
|
NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EME1 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Endod1 |
endonuclease domain containing 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ENDOD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eng |
endoglin |
multiple interactions |
ISO |
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of ENG protein] |
CTD |
PMID:30825431 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of ENO2 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Eny2 |
ENY2, transcription and export complex 2 subunit |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ENY2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 7:75,581,215...75,605,903
Ensembl chr 7:75,581,240...75,605,897
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases methylation |
ISO |
Cannabidiol results in decreased methylation of EPAS1 gene |
CTD |
PMID:33407853 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of EPB41L3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EPHX1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epn3 |
epsin 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EPN3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr10:79,438,978...79,449,516
Ensembl chr10:79,438,978...79,447,356
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ERAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression |
ISO |
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ERBB2 mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in decreased expression of ERBB2 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in decreased expression of ERBB2 mRNA] |
CTD |
PMID:32992648 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ERCC6 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Cannabidiol results in increased expression of EREG mRNA |
CTD |
PMID:36519830 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
increases expression |
ISO |
Cannabidiol results in increased expression of ERH protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,280,933...100,291,200
Ensembl chr 6:100,280,930...100,291,210
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression increases phosphorylation |
ISO |
Cannabidiol results in decreased expression of ERN1 mRNA Cannabidiol results in increased phosphorylation of ERN1 protein |
CTD |
PMID:31699976 PMID:33019509 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of ERRFI1 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
multiple interactions |
ISO |
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of ESPL1 mRNA] |
CTD |
PMID:30825431 |
|
NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
increases expression |
ISO |
Cannabidiol results in increased expression of ETS2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:35,021,536...35,038,322
Ensembl chr11:35,021,596...35,038,319
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EXO1 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Exosc4 |
exosome component 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of EXOSC4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:108,047,831...108,050,573
Ensembl chr 7:108,047,831...108,050,573
|
|
G |
Ezr |
ezrin |
affects methylation decreases expression |
EXP ISO |
Cannabidiol affects the methylation of EZR gene Cannabidiol results in decreased expression of EZR protein |
CTD |
PMID:30521419 PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Cannabidiol results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FAAH protein |
CTD |
PMID:33817834 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions decreases expression |
ISO |
Cannabidiol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] Cannabidiol results in decreased expression of FABP1 mRNA |
CTD |
PMID:31052254 PMID:31110286 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FADD mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FADS1 mRNA |
CTD |
PMID:31052254 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fam174c |
family with sequence similarity 174 member C |
increases expression |
ISO |
Cannabidiol results in increased expression of FAM174C mRNA |
CTD |
PMID:27918106 |
|
NCBI chr 7:9,531,995...9,533,705
|
|
G |
Fam217b |
family with sequence similarity 217, member B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FAM217B mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 3:165,505,574...165,515,273
Ensembl chr 3:165,501,532...165,513,377
|
|
G |
Fanca |
FA complementation group A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCA mRNA |
CTD |
PMID:36519830 |
|
NCBI chr19:51,304,126...51,362,586
Ensembl chr19:51,304,021...51,362,527
|
|
G |
Fancb |
FA complementation group B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCB mRNA |
CTD |
PMID:36519830 |
|
NCBI chr X:29,403,771...29,420,484
Ensembl chr X:29,403,771...29,420,192
|
|
G |
Fancc |
FA complementation group C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCC mRNA |
CTD |
PMID:36519830 |
|
NCBI chr17:1,680,660...1,822,610
Ensembl chr17:1,681,324...1,829,376
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCD2 mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fancg |
FA complementation group G |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCG mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
|
|
G |
Fanci |
FA complementation group I |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCI mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fancm |
FA complementation group M |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FANCM mRNA |
CTD |
PMID:36519830 |
|
NCBI chr 6:83,126,903...83,180,455
Ensembl chr 6:83,127,093...83,180,028
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of FAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of FAS mRNA [Cannabidiol co-treated with moringin] results in decreased expression of FAS mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of FAS mRNA |
CTD |
PMID:30096889 PMID:30742662 PMID:32400224 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of FASL mRNA |
CTD |
PMID:32400224 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases expression |
ISO |
Cannabidiol inhibits the reaction [Ethanol results in increased expression of FASN mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of FASN protein] Cannabidiol results in decreased expression of FASN mRNA |
CTD |
PMID:28935932 PMID:31052254 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of FBXO32 mRNA Cannabidiol results in increased expression of FBXO32 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FEN1 mRNA |
CTD |
PMID:33244087 PMID:36519830 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgd3 |
FYVE, RhoGEF and PH domain containing 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FGD3 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr17:15,324,848...15,387,271
Ensembl chr17:15,336,837...15,385,712
|
|
G |
Fgd4 |
FYVE, RhoGEF and PH domain containing 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of FGD4 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr11:84,399,989...84,551,013
Ensembl chr11:84,399,816...84,546,972
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of FGF1 mRNA Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF1 protein] |
CTD |
PMID:30825431 PMID:33244087 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF12 gene |
CTD |
PMID:30521419 |
|
NCBI chr11:71,997,151...72,564,757
Ensembl chr11:71,997,099...72,562,607
|
|
G |
Fgf14 |
fibroblast growth factor 14 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF14 gene |
CTD |
PMID:30521419 |
|
NCBI chr15:101,045,033...101,679,888
Ensembl chr15:101,045,036...101,679,900
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions increases expression |
ISO |
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF2 protein] Cannabidiol results in increased expression of FGF2 mRNA |
CTD |
PMID:27918106 PMID:30825431 PMID:36519830 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression multiple interactions |
ISO |
Cannabidiol analog results in increased expression of FGF21 mRNA Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of FGF21 protein]; Cannabidiol analog inhibits the reaction [Dietary Fats results in increased expression of FGF21 mRNA] |
CTD |
PMID:30382123 PMID:30825431 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions increases expression |
ISO |
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF7 protein] Cannabidiol inhibits the reaction [TNF protein results in increased expression of FGF7 mRNA] Cannabidiol results in increased expression of FGF7 mRNA |
CTD |
PMID:27918106 PMID:30825431 PMID:31250491 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR4 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
decreases methylation |
ISO |
Cannabidiol results in decreased methylation of FHL1 gene |
CTD |
PMID:33407853 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fis1 |
fission, mitochondrial 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FIS1 mRNA |
CTD |
PMID:27714895 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Fitm2 |
fat storage-inducing transmembrane protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FITM2 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 3:152,141,346...152,147,858
Ensembl chr 3:152,141,346...152,147,858
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of FKBP4 mRNA |
CTD |
PMID:27714895 |
|
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
|
|
G |
Fkbp8 |
FKBP prolyl isomerase 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of FKBP8 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:18,895,608...18,902,648
Ensembl chr16:18,893,576...18,902,612
|
|
G |
Flnc |
filamin C |
multiple interactions |
ISO |
[Cuprizone co-treated with Cannabidiol] results in decreased expression of FLNC protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of FLT1 mRNA [Cannabidiol co-treated with Dronabinol] results in increased expression of FLT1 mRNA alternative form |
CTD |
PMID:33872753 PMID:37567336 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
decreases expression |
ISO |
Cannabidiol results in decreased expression of FLT3LG mRNA |
CTD |
PMID:27932991 |
|
NCBI chr 1:95,615,056...95,620,463
Ensembl chr 1:95,609,370...95,620,463
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression multiple interactions |
ISO EXP |
Cannabidiol results in decreased expression of FOS mRNA Cannabidiol results in decreased expression of FOS protein Cannabidiol results in increased expression of FOS mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of FOS mRNA |
CTD |
PMID:21542829 PMID:27918106 PMID:28344069 PMID:30742662 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of FOSB mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxc2 |
forkhead box C2 |
increases expression |
ISO |
Cannabidiol results in increased expression of FOXC2 mRNA |
CTD |
PMID:27918106 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Foxd1 |
forkhead box D1 |
increases expression |
ISO |
Cannabidiol results in increased expression of FOXD1 mRNA |
CTD |
PMID:33244087 |
|
NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of FTH1 mRNA |
CTD |
PMID:31518892 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of FTL mRNA |
CTD |
PMID:31518892 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Ftmt |
ferritin mitochondrial |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Iron Carbonyl Compounds results in decreased expression of FTMT protein] |
CTD |
PMID:29374603 |
|
NCBI chr18:45,758,874...45,760,123
Ensembl chr18:45,758,874...45,760,123
|
|
<